Acquisitions (Tables)

12 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Schedule of Purchase Price Allocation

(in thousands)	Exiqon acquisition
Purchase Price:
Cash consideration	$	95,163
Fair value of remaining shares	5,519
	$	100,682
Preliminary Allocation:
Cash and cash equivalents	$	4,824
Accounts receivable	3,581
Inventory	1,553
Prepaid expenses and other current assets	1,853
Accounts payable	(1,289		)
Accruals and other current liabilities	(11,587		)
Debt assumed	(6,068		)
Other long-term liabilities	(197		)
Deferred tax asset on tax loss carry forwards	10,016
Fixed and other long-term assets	2,870
Developed technology	18,500
Customer relationships	3,800
Tradenames	1,400
Goodwill	76,807
Deferred tax liability on fair value of identifiable intangible assets acquired	(5,381		)
	$	100,682

The final purchase price allocation for Enzymatics was as follows:

(in thousands)	Enzymatics acquisition
Purchase Price:
Cash consideration	$	114,224
Fair value of contingent consideration	13,600
	$	127,824
Final Allocation:
Cash and cash equivalents	$	1,178
Accounts receivable	2,813
Prepaid expenses and other current assets	1,330
Fixed and other long-term assets	1,414
Accounts payable	(3,090		)
Accruals and other current liabilities	(1,940		)
Developed technology	28,600
Tradenames	6,600
Customer relationships	22,300
Goodwill	90,177
Deferred tax liability on fair value of identifiable intangible assets acquired	(21,558		)
	$	127,824